Antiplatelet agents in clinical practice and their haemorrhagic risk

Blood Transfusion

Volumn 11, Issue 3, 2013, Pages 349-356

  Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,4 DICHLOROBENZYL) 5 FLUORO 3 METHYL 1H INDOL 7 YL] N [(4,5 DICHLORO 2 THIENYL)SULFONYL]ACRYLAMIDE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; AJW 200; ALX 0081; ALX 0681; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APTAMER; ARC 15105; ATOPAXAR; CLOPIDOGREL; CONVULXIN; CYCLOOXYGENASE 1; DZ 697B; EGAPTIVON PEGOL; EMS 16; EXP 2179; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IB VON WILLEBRAND FACTOR INHIBITOR; GPG 290; HEPARIN; HIRULOG; NCX 6550; NCX 6560; NN PF 3; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; SNAKE VENOM; THROMBIN; THROMBIN RECEPTOR ANTAGONIST; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE; TRIFUNISAL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR; VORAPAXAR; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORTALITY; NONHUMAN; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOCYTE; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; CHEMICALLY INDUCED; HEMORRHAGE;

HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS;

EID: 84882345322     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0248-12     Document Type: Review

References (62)

1. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002; 23: 25-32.
2. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci 2008; 29: 352-60.
3. Vezza R, Mezzasoma AM, Venditti G, Gresele P. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets. Thromb Haemost 2002; 87: 114-21.
4. Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 1991; 12: 158-63.
5. Willoughby S, Loscalzo J. Vascular control of platelet function. In Gresele P, Page CP, Fuster V, Vermylen J, editors. Platelets in thrombotic and non-thrombotic disorders. Pathophysiology, pharmacology and therapeutics. Cambridge University Press; 2002. p. 432-58.
6. Reichenbach G, Momi S, Gresele P. Nitric oxide and its antithrombotic action in the cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 65-74.
7. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103: 56-61.
8. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002; 324: 71-86.
9. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
10. Hawkey CJ. Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut 2002; 50: III25-30.
11. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001; 119: 39S-63S.
12. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297: 2018-24.
13. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-7.
14. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin nonsteroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-8.
15. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
16. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
17. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
18. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
19. Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol 2007; 30: II24-34.
20. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-82.
21. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-6.
22. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-23.
23. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-STelevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-66.
24. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-30.
25. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-204.
26. Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009; 53: 2019-27.
27. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-62.
28. Romaguera R, Wakabayashi K, Laynez-Carnicero A, et al. Association between bleeding severity and long-term mortality in patients experiencing vascular complications after percutaneous coronary intervention. Am J Cardiol 2012; 109: 75-81.
29. Eikelboom JW, Cook RJ, Liu Y, Heddle NM. Duration of red cell storage before transfusion and in-hospital mortality. Am Heart J 2010; 159: 737-43.
30. Heddle NM, Cook RJ, Arnold DM, et al. The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. Transfusion 2012; 52: 1203-12.
31. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-64.
32. Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 2008; 118: 2139-45.
33. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
34. Gresele P. Perioperative handling of antiplatelet therapy: watching the two sides of the coin. Intern Emerg Med 2009; 4: 275-6.
35. Chan MY, Sun JL, Wang TY, et al. Patterns of discharge antiplatelet therapy and late outcomes among 8, 582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J 2010; 160: 1056-64.
36. Cattaneo M. The role of laboratory monitoring in antiplatelet therapy. In: Gresele P, Born GVR, Patrono C, Page CP, editors. Antiplatelet Agents. Handbook of Experimental Pharmacology. Berlin: Springer; 2012. p. 471-94.
37. Crescente M, Mezzasoma AM, Del Pinto M, et al. Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin. Platelets 2011; 22: 179-87.
38. Ambrosio G, Steinhubl S, Gresele P, et al. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: The ACUITY trial. Eur J Cardiovasc Prev Rehabil 2011; 18: 121-8.
39. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-54.
40. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821-30.
41. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-6.
42. Dalén M, van der Linden J, Lindvall G, Ivert T. Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery. Scand Cardiovasc J 2012; 46: 32-8.
43. Tsukahara K, Kimura K, Morita S, et al. Impact of highresponsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010; 74: 679-85.
44. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-8.
45. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012; 10: 199-206.
46. Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-46.
47. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-14.
48. Vandendries ER, Hamilton JR, Coughlin SR, et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A 2007; 104: 288-92.
49. Leonardi S, Becker RC. PAR-1 Inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. In: Gresele P, Born GVR, Patrono C, Page CP, editors. Antiplatelet Agents. Handbook of Experimental Pharmacology. Berlin: Springer; 2012. p. 239-60.
50. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, doubleblind, placebo-controlled phase II study. Lancet 2009; 373: 919-28.
51. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
52. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-13.
53. Gresele P, Momi S. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V. In: Gresele P, Born GVR, Patrono C, Page CP, editors. Antiplatelet Agents. Handbook of Experimental Pharmacology. Berlin: Springer 2012. p. 287-309.
54. Momi S, Tantucci M, Van Roy M, et al: Reperfusion of cerebral artery thrombosis by the GPIb/vWF blockade with nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood 2013; DOI 10.1182/blood-2012-11-464545.
55. Gresele P, Falcinelli E, Momi S. Platelet priming. In: Gresele P, Page CP, Fuster V, et al, editors. Platelets in Hematologic and Cardiovascular Disorders. Cambridge University Press; 2008. p. 53-78.
56. Gresele P, Falcinelli E, Loffredo F, et al. Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. Eur Heart J 2011; 32: 316-25.
57. Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med 2009; 206: 2365-79.
58. Vezza R, Roberti R, Nenci GG, Gresele P. Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 1993; 82: 2704-13.
59. Andre P. Intracellular signaling as a potential target for antiplatelet therapy. In: Gresele P, Born GVR, Patrono C, Page CP, editors. Antiplatelet Agents. Handbook of Experimental Pharmacology. Berlin: Springer; 2012. p. 339-67.
60. Freson K, Van Geet C. Novel targets for platelet inhibition. In: Gresele P, Born GVR, Patrono C, Page CP, Eds. Antiplatelet Agents. Handbook of Experimental Pharmacology. Berlin: Springer; 2012. p. 369-94.
61. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388-98.
62. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55: 2556-66.